JP2002332247A - Ｍｅｋ阻害剤の投与による好中球化学走性の治療または抑制方法 - Google Patents

Ｍｅｋ阻害剤の投与による好中球化学走性の治療または抑制方法

Info

Publication number
JP2002332247A
JP2002332247A JP2002132822A JP2002132822A JP2002332247A JP 2002332247 A JP2002332247 A JP 2002332247A JP 2002132822 A JP2002132822 A JP 2002132822A JP 2002132822 A JP2002132822 A JP 2002132822A JP 2002332247 A JP2002332247 A JP 2002332247A
Authority
JP
Japan
Prior art keywords
phenylamino
iodo
benzamide
methyl
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002132822A
Other languages
English (en)
Japanese (ja)
Inventor
Vijaykumar Mahalingappa Baragi
ヴィジャイクマール・マハーリンガッパ・バラーギ
Madhav Narasimha Devalaraja
マドハヴ・ナラシムハ・デヴァララージャ
Joseph Edwin Low
ジョウゼフ・エドウィン・ロウ
Vaishalee A Padgaonkar
ヴァイシャレー・アーヴィンド・パドガーオンカール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2002332247A publication Critical patent/JP2002332247A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2002132822A 2001-05-09 2002-05-08 Ｍｅｋ阻害剤の投与による好中球化学走性の治療または抑制方法 Pending JP2002332247A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28988101P 2001-05-09 2001-05-09
US60/289881 2001-05-09

Publications (1)

Publication Number Publication Date
JP2002332247A true JP2002332247A (ja) 2002-11-22

Family

ID=23113527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002132822A Pending JP2002332247A (ja) 2001-05-09 2002-05-08 Ｍｅｋ阻害剤の投与による好中球化学走性の治療または抑制方法

Country Status (12)

Country Link
US (1) US6972298B2 (enrdf_load_stackoverflow)
EP (1) EP1262176A1 (enrdf_load_stackoverflow)
JP (1) JP2002332247A (enrdf_load_stackoverflow)
KR (1) KR20020085852A (enrdf_load_stackoverflow)
CN (1) CN1383823A (enrdf_load_stackoverflow)
AU (1) AU3821502A (enrdf_load_stackoverflow)
CA (1) CA2385412A1 (enrdf_load_stackoverflow)
HU (1) HUP0201542A3 (enrdf_load_stackoverflow)
IL (1) IL149462A0 (enrdf_load_stackoverflow)
NZ (1) NZ518726A (enrdf_load_stackoverflow)
PL (1) PL353785A1 (enrdf_load_stackoverflow)
ZA (1) ZA200203668B (enrdf_load_stackoverflow)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509125A (ja) * 2003-10-21 2007-04-12 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｎ−〔（ｒ）−２，３−ジヒドロキシ−プロポキシ〕−３，４−ジフルオロ−２−（２−フルオロ−４−ヨード−フェニルアミノ）−ベンズアミドの多形
JPWO2005028426A1 (ja) * 2003-09-19 2007-11-15 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2298768A1 (en) 2004-06-11 2011-03-23 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US8575391B2 (en) 2004-07-26 2013-11-05 Chugai Seiyaku Kabushiki Kaisha 5-substituted-2-phenylamino benzamides as MEK inhibitors
JP2022024023A (ja) * 2016-11-18 2022-02-08 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005007616A1 (en) * 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7803839B2 (en) 2005-10-07 2010-09-28 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2008059513A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Compounds suitable as modulators of hdl
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
CA2686484A1 (en) * 2007-05-11 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
US8765815B2 (en) * 2007-09-20 2014-07-01 Ramot At Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
ES2557316T3 (es) 2009-09-08 2016-01-25 F. Hoffmann-La Roche Ag Compuestos de piridín-3-il-carboxamida 4-sustituidos y métodos de utilización
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP2600862B1 (en) 2010-08-05 2016-04-20 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
US20120095060A1 (en) * 2010-10-14 2012-04-19 Hardie William D Methods and compositions of mitogen-activated protein kinase (mapk) pathway inhibitors for treating pulmonary fibrosis
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
SG194051A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and vemurafenib, and methods of use
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
PE20151494A1 (es) 2012-10-12 2015-11-06 Exelixis Inc Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
EP3043790B1 (en) * 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
AU2018349376A1 (en) 2017-10-09 2020-05-07 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and TRPV1 channels and uses thereof
WO2019204569A1 (en) * 2018-04-20 2019-10-24 Thomas Jefferson University METHOD OF USING MeK INHIBITOR TO PREVENT RADIATION INDUCED FIBROSIS
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025043043A2 (en) * 2023-08-24 2025-02-27 Musc Foundation For Research Development Mek1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
DE69836378T2 (de) * 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
US6150401A (en) * 1998-01-06 2000-11-21 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
HUP0104607A3 (en) 1998-12-15 2002-12-28 Warner Lambert Co Use of a mek inhibitor for preventing transplant rejection
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
IL143939A0 (en) 1998-12-22 2002-04-21 Warner Lambert Co Combination chemotherapy
CA2350234A1 (en) * 1999-01-07 2000-07-13 Alexander James Bridges Treatment of asthma with mek inhibitors
HUP0104933A3 (en) 1999-01-07 2003-12-29 Warner Lambert Co Antiviral method using mek inhibitors
US6440966B1 (en) * 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
NZ515567A (en) 1999-07-16 2004-03-26 Warner Lambert Co Method for treating chronic pain using MEK inhibitors
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
DE60144277D1 (de) * 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
KR100773621B1 (ko) * 2000-07-19 2007-11-05 워너-램버트 캄파니 엘엘씨 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
AU2002249261A1 (en) 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
AU2002255852B2 (en) 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005028426A1 (ja) * 2003-09-19 2007-11-15 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US8084645B2 (en) 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
JP2007509125A (ja) * 2003-10-21 2007-04-12 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｎ−〔（ｒ）−２，３−ジヒドロキシ−プロポキシ〕−３，４−ジフルオロ−２−（２−フルオロ−４−ヨード−フェニルアミノ）−ベンズアミドの多形
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2298768A1 (en) 2004-06-11 2011-03-23 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US8835443B2 (en) 2004-06-11 2014-09-16 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US8575391B2 (en) 2004-07-26 2013-11-05 Chugai Seiyaku Kabushiki Kaisha 5-substituted-2-phenylamino benzamides as MEK inhibitors
JP2022024023A (ja) * 2016-11-18 2022-02-08 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン
JP7360434B2 (ja) 2016-11-18 2023-10-12 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン

Also Published As

Publication number Publication date
ZA200203668B (en) 2002-12-20
NZ518726A (en) 2004-06-25
HUP0201542A3 (en) 2003-10-28
AU3821502A (en) 2002-11-14
CN1383823A (zh) 2002-12-11
EP1262176A1 (en) 2002-12-04
IL149462A0 (en) 2002-11-10
US20030055095A1 (en) 2003-03-20
HUP0201542A2 (hu) 2003-01-28
US6972298B2 (en) 2005-12-06
CA2385412A1 (en) 2002-11-09
PL353785A1 (en) 2002-11-18
HU0201542D0 (enrdf_load_stackoverflow) 2002-07-29
KR20020085852A (ko) 2002-11-16

Similar Documents

Publication Publication Date Title
JP2002332247A (ja) Ｍｅｋ阻害剤の投与による好中球化学走性の治療または抑制方法
US6251943B1 (en) Method of treating or preventing septic shock by administering a MEK inhibitor
AU776788B2 (en) Treatment of arthritis with MEK inhibitors
EP1140062B1 (en) Treatment of asthma with mek inhibitors
ZA200104000B (en) Antiviral method using MEK inhibitors.
EP1140291B1 (en) Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
KR20010014360A (ko) 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도
AU5786000A (en) Method for treating chronic pain using mek inhibitors
CA2346684A1 (en) Use of a mek inhibitor for preventing transplant rejection
US20040171632A1 (en) Combination chemotherapy
KR20240142433A (ko) 폐 장애를 치료하기 위한 조성물 및 방법
US20200231545A1 (en) Charged ion channel blockers and methods for use thereof
ZA200104277B (en) Combination chemotherapy.
US20140107113A1 (en) Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060530